NASDAQ:JAGX

Jaguar Health Stock Insider Trading

Healthcare > Biotechnology

Buy JAGX

*Your capital is at risk

$2.92

-0.300 (-9.32%)

At Close: Jun 03, 2026

Jaguar Health Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 86.74. In total, the insiders bought 925.59K and sold 140.4K JAGX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	86.74
● Buy	925.59K shares
● Sell	140.4K shares
86% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence Jun 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 86.74. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Micek John Director	Director	7 377 Value: $10.6K
Dec 11, 2025 Buy	Common Stock A-Award	Micek John Director	Director	7 377 Value: $371.8K
Dec 11, 2025 Buy	Common Stock A-Award	King Steven R. See Remarks	Officer	11 740 Value: $591.7K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Wolin Jonathan S. See Remarks	Officer	11 740 Value: $16.9K
Dec 11, 2025 Buy	Common Stock A-Award	Wolin Jonathan S. See Remarks	Officer	11 740 Value: $591.7K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	King Steven R. See Remarks	Officer	11 740 Value: $16.9K
Dec 11, 2025 Buy	Common Stock A-Award	Conte Lisa A See Remarks	Officer	28 592 Value: $1.44M
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Conte Lisa A See Remarks	Officer	28 592 Value: $41.2K
Dec 11, 2025 Buy	Common Stock A-Award	Chaturvedi Pravin R Chief Scientific Officer	Officer	11 740 Value: $591.7K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Chaturvedi Pravin R Chief Scientific Officer	Officer	11 740 Value: $16.9K
Dec 11, 2025 Buy	Common Stock A-Award	Bochnowski James J Director	Director	6 363 Value: $320.7K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Bochnowski James J Director	Director	6 363 Value: $9K
Dec 11, 2025 Buy	Common Stock A-Award	Siegel Jonathan B. Director	Director	7 377 Value: $371.8K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Siegel Jonathan B. Director	Director	7 377 Value: $10.6K
Dec 11, 2025 Buy	Common Stock A-Award	Jayasuriya Anula Director	Director	5 870 Value: $295.8K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Jayasuriya Anula Director	Director	5 870 Value: $8K
Dec 11, 2025 Buy	Common Stock A-Award	Lizak Carol R. Chief Financial Officer	C-Suite Officer	11 740 Value: $591.7K
Dec 11, 2025 Buy	Stock Option (right to buy) A-Award	Lizak Carol R. Chief Financial Officer	C-Suite Officer	11 740 Value: $16.9K
Aug 28, 2025 Buy	Common Stock, par value $0.0001 per share	Lincoln Alternative Strategies Llc 10 Percent Owner	10% Owner	0 Value: $0
Aug 28, 2025 Buy	Common Stock, par value $0.0001 per share	Lincoln Alternative Strategies Llc 10 Percent Owner	10% Owner	0 Value: $0
Jun 24, 2025 Buy	Convertible Promissory Note A-Award	Siegel Jonathan B. Director	Director	9 462 Value: $52.6K
Jun 24, 2025 Buy	Warrant to Purchase Common Stock A-Award	Siegel Jonathan B. Director	Director	18 262 Value: $49.3K
Jun 24, 2025 Sell	Convertible Promissory Note D-Return	Siegel Jonathan B. Director	Director	9 000 Value: $50.0K
Jun 24, 2025 Buy	Convertible Promissory Note A-Award	Micek John Director	Director	9 462 Value: $52.6K
Jun 24, 2025 Buy	Warrant to Purchase Common Stock A-Award	Micek John Director	Director	18 262 Value: $49.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT JAGUAR HEALTH, INC.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer fo...

Read Full Profile Here